Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment Acta Haematol 2013;129:207–214 - DOI:10.1159/000345260 Fig. 1. The intracellular pathways and proteins affected by proteasome inhibition with bortezomib. Ros = Reactive oxygen species; JNK = c-Jun N-terminal kinase. © 2013 S. Karger AG, Basel
Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment Acta Haematol 2013;129:207–214 - DOI:10.1159/000345260 Fig. 2. Bortezomib treatment led to inhibition of BCR-ABL-induced suppression of FoxO proteins and their proapoptotic targets in Ph + ALL patients. © 2013 S. Karger AG, Basel